Phase II Trials in Drug Development and Adaptive Trial Design

Phase II clinical studies represent a critical point in determining drug costs, and phase II is a poor predictor of drug success: >30% of drugs entering phase II studies fail to progress, and >58% of drugs go on to fail in phase III. Adaptive clinical trial design has been proposed as a way to...

Descripción completa

Detalles Bibliográficos
Autor principal: Van Norman, Gail A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
TRANSLATIONAL TOOLBOX
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609997/
https://www.ncbi.nlm.nih.gov/pubmed/31312766
http://dx.doi.org/10.1016/j.jacbts.2019.02.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609997/
https://www.ncbi.nlm.nih.gov/pubmed/31312766
http://dx.doi.org/10.1016/j.jacbts.2019.02.005

Ejemplares similares